Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.

Name: Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.
Author: Dodero, A

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. — المؤلف: Dodero, A — Leukemia 20190809

المؤلف: Dodero, A
النشر: Leukemia 20190809
الوصف: 1047-1051 p.
الموضوعات: Adult؛ Aged؛ Aged, 80 and over؛ Antineoplastic Combined Chemotherapy Protocols؛ Cyclophosphamide؛ Dose-Response Relationship, Drug؛ Doxorubicin؛ Etoposide